Sodium Hyaluronate Increases the Fibrinolytic Response of Human Peritoneal Mesothelial Cells Exposed to Tumor Necrosis Factor α

Michel M. P. J. Reijnen, MD; Harry van Goor, MD, PhD; Peter Falk, BSc; Maria Hedgren, BSc; Lena Holmdahl, MD, PhD

Hypothesis: Sodium hyaluronate interferes with the fibrin degrading capacity of human peritoneal mesothelial cells exposed to tumor necrosis factor (TNF) α.

Design: Controlled laboratory experiment.

Intervention: Human peritoneal mesothelial cells were harvested from 5 patients undergoing laparotomy and cultured in vitro. Cells were treated with TNF-α, a cytokine typically involved in peritoneal inflammation, and sodium hyaluronate was added in a final concentration of 0.1%, 0.2%, or 0.4%. Controls received medium only. After 24 hours' incubation, tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and plasminogen activator inhibitor type 1 (PAI-1) were measured in the medium and cell lysates using enzyme-linked immunosorbent assay techniques. Specific gene transcripts in cells treated with 0.4% sodium hyaluronate and controls were determined using a quantitative reverse transcription polymerase chain reaction.

Main Outcome Measures: Concentrations of tPA, uPA, and PAI-1, and their specific gene transcripts.

Results: Sodium hyaluronate significantly increased tPA concentration in cell lysates without affecting its gene expression as determined after 24 hours ($P = .02$). The uPA concentration was significantly decreased by sodium hyaluronate in the medium but not in cell lysates ($P < .0001$). The uPA messenger RNA expression was 1000-fold increased compared with control. Sodium hyaluronate significantly decreased PAI-1 concentration in the medium and reduced its gene expression 500-fold ($P = .04$), while PAI-1 concentration in cell lysates did not change.

Conclusion: Sodium hyaluronate affected the fibrinolytic response of TNF-α–stimulated human peritoneal mesothelial cells, most notably by decreasing PAI-1 transcription and release. This observation indicates that sodium hyaluronate counteracts the fibrinolytic decline induced by TNF-α and suggests a biological mechanism of action for sodium hyaluronate intra-abdominally.


Peritoneal injury from a variety of causes leads to peritoneal inflammation, including exudation of fibrinogen and fibrin formation into the abdominal cavity. These fibrin deposits may in turn become fibrous adhesions due to collagen deposition by invading fibroblasts. In an infectious environment, adhesions may form as a part of an abscess. Both intra-abdominal adhesions and abscesses cause significant clinical morbidity and mortality.

Intra-abdominal fibrin is degraded by the fibrinolytic system through the action of plasmin, which is enzymatically converted from plasminogen. By producing both plasminogen activators and inhibitors, mesothelial cells are crucial in the regulation of fibrinolytic capacity. Tissue-type plasminogen activator (tPA) is the main plasminogen activator, responsible for approximately 95% of plasminogen activator activity. A second plasminogen activator is urokinase-type plasminogen activator (uPA), which appears to play an important role in tissue remodeling, but its role in intra-abdominal adhesion formation is not well defined. Their activity is restricted by plasminogen activator inhibitor type 1 (PAI-1) and type 2 (PAI-2). A reduced peritoneal fibrinolytic capacity is induced by abdominal surgery and infection, predominantly resulting from high PAI-1 concentrations and to a lesser extent from low tPA levels. A high peritoneal PAI-1 concentration has been associated with severe adhesion formation.

It has been demonstrated that postsurgical adhesion formation was reduced by a sodium hyaluronate solution when administered in the peritoneal cavity during surgery. The effect of hyaluronate was attributed to protection of peritoneal surfaces from surgical trauma. We, however, showed a reduction of intra-abdominal adhesions and even abscesses in a rat peritonitis model, wherein the hyal-
MATERIALS AND METHODS

MESOTHELIAL CELLS

Human peritoneal mesothelial cells were isolated from peritoneal lavage performed on 3 patients undergoing colorectal surgery for noninfectious reasons by use of the method described by Ivarsson et al.9 Meticulous hemostasis during opening of the abdomen prevented blood spill into the lavage fluid. We transferred the lavage fluid into 50-mL tubes and centrifuged the fluid at 650g for 10 minutes. The supernatant was withdrawn, and the pellet was resuspended in 5 mL of culture medium.

Cells were cultured at 37°C in 5% CO2 in air with a humidity of 80% to 90%, in tissue culture flasks (25 cm2) (Sarstedt, Newton, NC) in a medium that consisted of E199 (Sigma, St Louis, Mo), with the addition of L-glutamine, 1.1 mmol/L (Sigma); penicillin-streptomycin, 30 IE/mL (Sigma); fetal bovine serum, 20% (Sigma); endothelial cell growth factor, 50 µg/mL, prepared according to Maciag et al15; heparin, 14 IU/mL (Lovens Lakemedel, Malmö, Sweden); and 0.3 µg/mL hydrocortisone (Sigma). All cells used were from the third passage. The mesothelial origin from the cells was verified by their typical cobblestone appearance in phase-contrast microscopy and by immunohistochemical analysis, as previously described.13

STUDY DESIGN

Human peritoneal mesothelial cells were cultured until a confluent monolayer was formed. The TNF-α (TNF-8; Genzyme, Cambridge, Mass) was added to the medium in a final concentration of 500 Unit/mL. Immediately after, sodium hyaluronate solution was applied 24 hours after the initial peritoneal lavage performed on 5 patients undergoing colorectal surgery for noninfectious reasons by use of the method described by Ivarsson et al.9 Meticulous hemostasis during opening of the abdomen prevented blood spill into the lavage fluid. We transferred the lavage fluid into 50-mL tubes and centrifuged the fluid at 650g for 10 minutes. The supernatant was withdrawn, and the pellet was resuspended in 5 mL of culture medium.

Cells were cultured at 37°C in 5% CO2 in air with a humidity of 80% to 90%, in tissue culture flasks (25 cm²) (Sarstedt, Newton, NC) in a medium that consisted of E199 (Sigma, St Louis, Mo), with the addition of L-glutamine, 1.1 mmol/L (Sigma); penicillin-streptomycin, 30 IE/mL (Sigma); fetal bovine serum, 20% (Sigma); endothelial cell growth factor, 50 µg/mL, prepared according to Maciag et al15; heparin, 14 IU/mL (Lovens Lakemedel, Malmö, Sweden); and 0.3 µg/mL hydrocortisone (Sigma). All cells used were from the third passage. The mesothelial origin from the cells was verified by their typical cobblestone appearance in phase-contrast microscopy and by immunohistochemical analysis, as previously described.13

RESULTS

TISSUE-TYPE PLASMINOGEN ACTIVATOR

The tPA concentration in the medium was not significantly influenced by treatment with sodium hyaluronate (P = 0.7) (Figure 2). In contrast to the medium, tPA concentration in cell lysates was significantly increased by treatment with sodium hyaluronate (P = 0.02) (Figure 3), but there was no significant difference in...
tPA concentration between groups treated with different concentrations of sodium hyaluronate. The tPA mRNA expression in controls was $1 \times 10^6$ mRNA copies per micrograms of total RNA per cell. Incubation with 0.4% sodium hyaluronate did not change tPA mRNA expression (Figure 4).

**UROKINASE-TYPE PLASMINOGEN ACTIVATOR**

Sodium hyaluronate significantly decreased uPA concentration in the medium compared with control ($P<.0001$) (Figure 5). Treatment with 0.4% sodium hyaluronate significantly lowered uPA concentrations in comparison with 0.1% and 0.2% sodium hyaluronate ($P<.001$ and $P=.001$, respectively). In cell lysates, sodium hyaluronate did not significantly affect uPA concentration compared with controls (Figure 6).

The uPA mRNA expression in control cells was $2 \times 10^2$ mRNA copies per microgram of total RNA. Treatment with 0.4% sodium hyaluronate caused a 1000-fold increase in uPA mRNA expression to $4 \times 10^5$ mRNA copies per microgram of total RNA (Figure 4).

**PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1**

Incubation with sodium hyaluronate significantly decreased PAI-1 concentration in the medium ($P=.04$) (Figure 7). Treatment with 0.4%, but not 0.1% and 0.2% sodium hyaluronate, significantly decreased PAI-1 concentrations compared with controls ($P=.02$). There was no significant difference in PAI-1 concentration between groups treated with different concentrations of sodium hyaluronate. In cell lysates, sodium hyaluronate did not significantly affect PAI-1 levels compared with controls (Figure 8).

The PAI-1 mRNA expression in control cells was $6 \times 10^4$ mRNA copies per microgram of total RNA per cell. Treatment with 0.4% sodium hyaluronate caused a 500-fold decrease in PAI-1 mRNA expression to $1 \times 10^2$ mRNA copies per microgram of total RNA (Figure 4).

**COMMENT**

Hyaluronan-based agents prevent adhesions after abdominal surgery. Becker et al described a significant reduction in postoperative adhesion formation in patients undergoing colectomy and ileal pouch anal anastomosis with temporary diverting loop enterostomy for ulcerative colitis or familial polyposis, using a biodegradable membrane consisting of hyaluronan and carboxymethylcellulose. Similar results were found using this membrane in a prospective multicenter randomized trial.
of gynecologic patients undergoing myomectomy. Moreover, Diamond reported the efficacy of sodium hyaluronate, used as a precoating solution, in prevention of de novo adhesions in patients undergoing laparotomy for various benign gynecologic disorders. The adhesion-reducing capacity of hyaluronan-based bioresorbable membrane has been attributed to mechanical properties, separating damaged peritoneal surfaces that tend to adhere during the first days after surgery. A solution of hyaluronan, applied at abdominal entry, is thought to prevent inadvertent peritoneal trauma during surgery, thereby reducing the formation of adhesions.

We demonstrated that intraperitoneal treatment with sodium hyaluronate solution reduced adhesion and abscess formation in rats with bacterial peritonitis. In the study the solution was administered 24 hours after induction of a bacterial peritonitis, thus the reduction in adhesions and abscesses cannot be attributed to properties related to protective coating. Modulation of the fibrinolytic response in the abdominal cavity was hypothesized as a possible explanation for those findings.

Fibrin depositions occur in the abdominal cavity in response to trauma such as surgery or infection and are considered as the basis of both adhesions and abscesses. The local balance between fibrin deposition and degradation is decisive in adhesion formation, as recently reviewed. Reduction in fibrin-degrading capacity has been observed during abdominal operation and in peritonitis. Elevated PAI-1 concentrations in peritoneal tissue and fluid, and to a lesser extent a decline in the main fibrinolytic stimulator tPA, are responsible for the fibrinolytic impairment. Consequently, down-regulation of PAI-1 in particular would increase the fibrinolytic capacity and might restore the balance between fibrin formation and degradation.

A common denominator in the postoperative period and in peritonitis is an increase in intra-abdominal concentration of proinflammatory cytokines, most notably TNF-α. Because fibrin deposition is a prerequisite for abscess and adhesion formation, we chose to investigate the influence of hyaluronate on the fibrin degradation capacity in the presence of TNF-α. Human peritoneal mesothelial cells, harvested by peritoneal lavage and cultured in vitro, react to TNF-α exposure by an increase in PAI-1 and a decrease in tPA production, consequently depressing plasminogen acti-

Figure 3. Levels of tissue-type plasminogen activator (tPA) antigen in cell lysates. Results are illustrated as median (horizontal line) interquartile range (boxes) and 10th and 90th percentiles (error bars).

Figure 4. Number of tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and plasminogen activator inhibitor type 1 (PAI-1) messenger RNA (mRNA) copies per micromgram of total RNA in human peritoneal mesothelial cells cultured in the medium with (solid bars) or without (open bars) 0.4% sodium hyaluronate. The presence of sodium hyaluronate decreased the mRNA expression for PAI-1 and increased expression for uPA compared with untreated controls, indicating a possible regulatory effect at the transcriptional level.

Figure 5. Levels of urokinase-type plasminogen activator (uPA) antigen in conditioned media. Results are illustrated as median (horizontal line) interquartile range (boxes) and 10th and 90th percentiles (error bars).

Figure 6. Levels of urokinase-type plasminogen activator (uPA) antigen in cell lysates. Results are illustrated as median (horizontal line) interquartile range (boxes) and 10th and 90th percentiles (error bars).
Urokinase-type plasminogen activator antigen concentrations remain unaffected by treatment with TNF-α. Urokinase-type plasminogen activator (tPA) expression is conceived to be a major reason for the decrease in peritoneal fibrin degradation capacity and demonstrated to be a marker of increased propensity for the development of adhesions, a regulatory effect on mesothelial PAI-1 expression could therefore have a major influence in the series of events leading to adhesions or abscesses. The effect of sodium hyaluronate on tPA expression seemed to be limited but nevertheless resulted in increased intracellular concentration, probably due to intracellular pooling, as is previously described for endothelial cells. This suggests that sodium hyaluronate affected the tPA production pathway at the posttranslational level. Alternatively, intracellular tPA degradation may be inhibited, a phenomenon that has been reported earlier for chloroquine and receptor-associated protein. Although there is no indication that the increased intracellular storage of tPA was transcriptionally regulated, this cannot be ruled out with the current experimental design, and further studies investigating this are warranted. As for uPA, on the other hand, there was an increased transcription that did not result in increased intracellular or extracellular concentration of the protein, suggesting a posttranscriptional block. Thus, the effects of sodium hyaluronate on mesothelial cell production in a proinflammatory environment seem complex, but nevertheless result in an increased plasminogen activation by decreasing the extracellular expression of the main inhibitor PAI-1.

The mechanism by which sodium hyaluronate affects mesothelial fibrinolysis is unknown. Sodium hyaluronate may interfere with TNF-α stimulation on the mesothelial cells by direct binding to TNF-α or by competing at the TNF-α receptor level. Blocking transforming growth factor β (TGF-β) at either its signal transduction receptors or its TNF-α-dependent production by the mesothelial cells might be another explanation for the decrease in PAI-1 caused by sodium hyaluronate. The TGF-β influences PAI-1 production of the mesothelial cells at the transcriptional level and is associated with elevated PAI-1 levels in peritoneal tissues. A toxic effect of sodium hyaluronate on the mesothelial cells is not likely because cells were viable and proliferating 24 hours after administration of sodium hyaluronate. Moreover, it was previously demonstrated that sodium hyaluronate causes mesothelial cell proliferation, even in the presence of TNF-α and/or lipopolysaccharide. Finally, sodium hyaluronate may exert its effect by binding to hyaluronan receptors as CD44, receptor for hyaluronate-mediated motility, and intercellular adhesion molecule-1. Mesothelial cells have the CD44 receptor on their cell surface. This receptor has a role in inflammatory conditions, allograft rejection, and tumor migration. An association, however, between this receptor and the production of components of the fibrinolytic system has to our knowledge not been demonstrated.

Abdominal surgery and infection cause extensive damage to the peritoneum, including the mesothelial monolayer. An episode of peritoneal damage is followed by repair mechanisms, including repopulation of peritoneal surfaces with mesothelial cells and the lysis of intra-abdominal fibrin by the abdominal fibrinolytic system. Results from the present study suggest that the biology of postsurgical peritoneal repair is modulated by hyaluronan. By increasing the fibrinolytic response of mesothelial cells, the instillation of hyaluronan in the abdominal cavity might be useful in clinical situations wherein excess fibrin is considered to be harmful. Hyaluronan used as a peritoneal instillate, or as a lavage solution, may prevent adhesions and abscesses in bacterial peritonitis, as was earlier demonstrated. Patients on continuous ambulatory peritoneal dialysis (CAPD) might benefit from lavage with hyaluronate when experiencing CAPD peritonitis. This type of peritonitis induces intra-abdominal adhesions, which in turn decrease the peritoneal surface needed for dialyzing and ultimately may cause CAPD failure. Further studies are needed to determine the benefit of hyaluronate in these clinical conditions.
Sodium hyaluronate increases the fibrinolytic response of human peritoneal mesothelial cells exposed to tumor necrosis factor α. Results described in the article indicate that hyaluronate, currently used in antiadhesive barrier materials, influences the fibrinolytic activity of the peritoneum under inflammatory conditions. The fibrinolytic activity of human peritoneal mesothelial cells is enhanced by treatment with hyaluronate, particularly by suppression of plasminogen activator inhibitor. An increased fibrinolytic activity in the abdominal cavity is considered beneficial for the reduction of intra-abdominal adhesions and abscesses. Postsurgical adhesions are the most common cause of small bowel obstruction and secondary female infertility and may be related to chronic abdominal pain. Adhesive small bowel obstruction is the reason for 1% of admissions to general surgery. Intra-abdominal abscesses are an important cause of morbidity and mortality in patients after (generalized) peritonitis.

Enhancement of the peritoneal fibrinolytic activity is particularly indicated in clinical situations wherein excess fibrin is formed. Examples hereof are generalized peritonitis, repeated laparotomies and continuous ambulatory peritoneal dialysis peritonitis. Use of hyaluronate, for example in peritoneal perioperative lavage fluid may, based on its property to enhance the fibrinolytic activity of peritoneal mesothelial cells, play a role to reduce adhesion and abscess related complications.

In summary, in an inflammatory environment, mesothelial cell fibrinolysis is affected by sodium hyaluronate most notably by a down-regulation of PAI-1 at the gene and protein level. This finding gives further support to the notion that barrier materials designed to reduce adhesion formation do not act solely through a mechanical action but might have a profound impact on peritoneal biology. Furthermore, the observation suggests that sodium hyaluronate may in part reduce adhesions and abscesses through increased fibrinolysis by reducing PAI-1 expression in the peritoneal cavity.

This work was supported by grants from the Surgical Infection Society of Europe (Dr Reijnen) and the Swedish Medical Research Council (project K98-17X-12650) (Dr Holmdahl).

This sodium hyaluronate was generously donated by the Genzyme Corporation, Cambridge, Mass.

Corresponding author and reprint: Michel M. P. J. Reijnen, MD, Department of Surgery, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands (e-mail: MMPJ.Reijnen@worldonline.nl).

REFERENCES